KR920700225A - Grf 유사체 viia - Google Patents

Grf 유사체 viia

Info

Publication number
KR920700225A
KR920700225A KR1019900702671A KR900702671A KR920700225A KR 920700225 A KR920700225 A KR 920700225A KR 1019900702671 A KR1019900702671 A KR 1019900702671A KR 900702671 A KR900702671 A KR 900702671A KR 920700225 A KR920700225 A KR 920700225A
Authority
KR
South Korea
Prior art keywords
ala
arg
leu
gln
ser
Prior art date
Application number
KR1019900702671A
Other languages
English (en)
Other versions
KR0163033B1 (ko
Inventor
에도우어드 프레드릭 리비어 진
워커 발리 쥬니어 와일리
라우레 리비어 카테린
Original Assignee
원본미기재
더 솔크 인스티튜트 포오 바이오로지칼 스터디이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 솔크 인스티튜트 포오 바이오로지칼 스터디이즈 filed Critical 원본미기재
Publication of KR920700225A publication Critical patent/KR920700225A/ko
Application granted granted Critical
Publication of KR0163033B1 publication Critical patent/KR0163033B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

GRF 유사체 VIIA
내용없음

Claims (10)

  1. 다음 식을 갖는 합성 펩티드.
    〔Na, MeTyr1, Ala15,CML23, Nle27, Asn28〕－hGRF(1－29)－NH2;〔Na, MeTyr1, Ala15, CMA17, Nle27, Asn28〕－hGRF(1－29)－NH2;〔Na, MeTyr1, Ala15, CML26, Nle27, Asn28〕－hGRF(1－29)－NH2; 또는〔Na, MeTyr1, Ala15, CML27, Nle27, Asn28〕－hGRF(1－29)－NH2.
  2. 다음 서열을 갖는 합성 펩티드, 또는 그의 무독성 염.
    (B)R1－R2－R3－Ala－(Q1)R5－Phe－Thr－R8－Ser－(Q2)R10－Arg－R12－(Q3)R13－Leu－R15－Gln－(Q4)Leu－R18－(Q5)Ala－Arg－R21－(Q6)R22－(Q7)Leu－R24－R25－(Q8)R26－(Q9)－R27－R28－Arg－Gln－Gln－Gly－Glu－R34－Asn－Gln－GLU－R38－R39－R40－Arg－R42－R43－R44(식에서, R1은 Tyr, D－Tyr, Met, Phe, D－Phe, pCl－Phe, Leu, His 또는 D－His; B는 H, C Me, 데스 아미노, Ac 또는 For; R2는 Ala, D－Ala, NMA 또는 D－NMA; R3는 Asp 또는 D－Asp; R5는 Ile 또는 Leu; R8는 Ser, Asn, Lys, Arg, Asp 또는 Glu; R10은 Tyr, D－Tyr 또는 Phe; R12는 Arg 또는 Lys; R13DMS Ile, Val, Leu 또는 Ala; R15는 Gly 또는 Ala; R18는 Ser 또는 Tyr; R21는 Lys, D－Lys, Arg 또는 D－Arg; R22는 Leu, Ile, Ala 또는 Val; R24는 Gln 또는 His; R25는 Asp 또는 Glu; R26는 Ile 또는 Leu; R27는 Met, D－Met, Ala, Nle, Ile, Leu, Nva 또는 Val; R28는 Asn 또는 Ser; R34는 Ser 또는 Arg; R38는 Arg 또는 Gln; R39는 Gly 또는 Arg; R40은 Ala 또는 Ser; R42는 Phe, Ala 또는 Val; R43는 Asn 또는 Arg; R44는 천연 아미노산; Q1－Q9은 H 또는 CaMe이며 단, R30과 R44사이의 임의의 잔기 또는 모든 잔기가 C－말단에서 시작하는 서열에서 삭제될수 있고, 또한 단, Q1,Q4, Q7, Q8및 Q9중 하나 이상이 CaMe이다).
  3. 제2항에 있어서, R27은 Nle이며 30부터 44까지의 잔기가 삭제되는 펩티드.
  4. 제2항에 있어서, R15는 Ala 이며 R28은 Asn인 펩티드.
  5. 제2항에 있어서, Q1은 CaMe인 펩티드.
  6. 제2항에 있어서, Q4은 CaMe인 펩티드.
  7. 제2항에 있어서, Q7은 CaMe인 펩티드.
  8. 제2항에 있어서, Q8은 CaMe인 펩티드.
  9. 제2항에 있어서, Q9은 CaMe인 펩티드.
  10. 다음 식을 갖는 합성 펩티드, 또는 그의 무독성 염.
    (B)R1－R2－R3－Ala－(Q1)R5－Phe－Thr－R8－Ser－(Q2)R10－Arg－R12－(Q3)R13－Leu－R15－Gln－(Q4)Leu－R18－(Q5)Ala－Arg－R21－(Q6)R22－(Q7)Leu－R24－R25－(Q8)R26－(Q9)－R27－R28－Arg－Gln－Gln－Gly－Y(식에서, R1은 Tyr, D－Tyr, Phe, D－Phe, His 또는 D－His; B는 H, CaMe, 또는 NaMe; R2는 Ala, D－Ala, NMA 또는 D－NMA; R8는 Ser, Asn, Lys, Arg, Asp 또는 Glu; R10은 Tyr, D－Tyr 또는 Phe; R12는 Arg 또는 Lys; R13은 Ile, Val, Leu 또는 Ala; R15는 Gly 또는 Ala; R18는 Ser 또는 Tyr; R21는 Lys, D－Lys, Arg 또는 D－Arg; R22는 Leu, Ile, Ala 또는 Val; R24는 Gln 또는 His; R25는 Asp 또는 Glu; R27는 Met, Ala, Nle, Ile, Leu, Nva 또는 Val; R28는 Asn 또는 Ser; Y는 R이 H 또는 저급 알킬인 NHR; Q1－Q9는 H 또는 CaMe이며 단, Gly, Gln－Gly 또는 Gln－Gln－Gly가 C－말단에서 삭제될 수 있고, 또한 단, Q1, Q4, Q7, Q8및 Q9중 하나이상이 CaMe 이다).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900702671A 1989-04-25 1990-04-24 Grf 유사체 viia KR0163033B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US342751 1989-04-25
US07/342,751 US5098995A (en) 1987-05-22 1989-04-25 GRF Analogs VIIA
US342,751 1989-04-25

Publications (2)

Publication Number Publication Date
KR920700225A true KR920700225A (ko) 1992-02-19
KR0163033B1 KR0163033B1 (ko) 1998-11-16

Family

ID=23343123

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702671A KR0163033B1 (ko) 1989-04-25 1990-04-24 Grf 유사체 viia

Country Status (14)

Country Link
US (1) US5098995A (ko)
EP (1) EP0423322B1 (ko)
JP (1) JP2974254B2 (ko)
KR (1) KR0163033B1 (ko)
AT (1) ATE133687T1 (ko)
AU (1) AU628558B2 (ko)
CA (1) CA2030810C (ko)
DE (1) DE69025123T2 (ko)
DK (1) DK0423322T3 (ko)
ES (1) ES2085350T3 (ko)
FI (1) FI94356C (ko)
IL (1) IL94171A (ko)
NO (1) NO178031C (ko)
WO (1) WO1990012810A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756458A (en) * 1989-06-16 1998-05-26 Pharmacia & Upjohn Company Stabilized potent GRF analogs
CA2106765A1 (en) * 1991-04-24 1992-11-12 David C. Horwell Cck analogs containing ó-substituted amino acids
CA2106764A1 (en) * 1991-04-24 1992-10-25 David C. Horwell Ó-substituted polypeptides having therapeutic activity
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
CA2158782C (en) * 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
DE60333270D1 (de) * 2002-04-29 2010-08-19 Euro Celtique Sa Den orl-1-rezeptor bindende peptide mit eingeschränkter konformation
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
EP2934565B1 (en) 2012-12-21 2019-03-13 University of Miami Ghrh agonists for the treatment of ischemic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728726A (en) * 1982-10-04 1988-03-01 The Salk Institute For Biological Studies GRF analogs IIIb
US4594329A (en) * 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
US4689318A (en) * 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US5002931A (en) * 1987-05-22 1991-03-26 The Salk Institute For Biological Studies GRF analogs VII

Also Published As

Publication number Publication date
NO178031B (no) 1995-10-02
NO905505D0 (no) 1990-12-20
ES2085350T3 (es) 1996-06-01
DE69025123D1 (de) 1996-03-14
IL94171A0 (en) 1991-01-31
DE69025123T2 (de) 1996-09-19
WO1990012810A1 (en) 1990-11-01
ATE133687T1 (de) 1996-02-15
US5098995A (en) 1992-03-24
DK0423322T3 (da) 1996-06-24
IL94171A (en) 1994-11-11
FI94356C (fi) 1995-08-25
JPH04500526A (ja) 1992-01-30
AU5556990A (en) 1990-11-16
FI94356B (fi) 1995-05-15
EP0423322B1 (en) 1996-01-31
NO905505L (no) 1991-02-20
EP0423322A1 (en) 1991-04-24
KR0163033B1 (ko) 1998-11-16
CA2030810A1 (en) 1990-10-26
JP2974254B2 (ja) 1999-11-10
CA2030810C (en) 1999-12-14
AU628558B2 (en) 1992-09-17
NO178031C (no) 1996-01-10
FI906240A0 (fi) 1990-12-18

Similar Documents

Publication Publication Date Title
ES8600217A1 (es) Un procedimiento para producir peptidos que influyen en la funcion de la glandula pituitaria
EG17394A (en) G r f analogs iv
ES2001274A6 (es) Un metodo para preparar peptidos que tienen influencia sobre la funcion de la glandula pituitaria en seres humanos y otros animales
ATE103609T1 (de) Zyklische grf-analoge.
KR930701483A (ko) Grf (쥐이알에프) 유사체 xi
KR920700225A (ko) Grf 유사체 viia

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040920

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee